ENDRA Life Sciences Inc. is a company that has developed Thermo-Acoustic Enhanced UltraSound (TAEUS®) technology, which enables clinicians to see tissue in ways previously possible only with CT or MRI, at a fraction of the cost and at the point of care. The company is focused on enhancing ultrasound technology to improve the diagnosis and monitoring of complex diseases, particularly liver diseases like Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

COM:ENDRAINC

ENDRA Life Sciences Inc.

Last Close

0.42

30/08 20:00

Market Cap

6.18M

Beta: -

Volume Today

3.20M

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics